Cantor Fitzgerald assumed coverage of Neurocrine with an Overweight rating and price target of $140, up from $135. The company has demonstrated “excellent execution” with the development and commercialization of Ingrezza for for tardive dyskinesia, but it has struggled to diversify its portfolio with novel target programs, the analyst tells investors in a research note. The firm believes crinecerfont for congenital adrenal hyperplasia can be a blockbuster product based on specialist commentary and benchmarking to other endo drugs.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine price target raised to $143 from $137 at BofA
- Neurocrine price target raised to $135 from $125 at Leerink
- Neurocrine price target raised to $157 from $152 at Baird
- Neurocrine price target raised to $165 from $160 at Oppenheimer
- Neurocrine price target raised to $150 from $146 at H.C. Wainwright